Determination That PARAFON FORTE DSC (Chlorzoxazone) Tablets, 500 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 45507 [2016-16635]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 135 / Thursday, July 14, 2016 / Notices
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in section 552b(c)(4) and (6), title 5
U.S.C., and the determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters for Discussion: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Emerging Infections Programs’’,
FOA CK17–1701.
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H., Scientific
Review Officer, CDC, 1600 Clifton Road NE.,
Mailstop E60, Atlanta, Georgia 30333,
Telephone: (404) 718–8833.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2016–16581 Filed 7–13–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–P–4224]
Determination That PARAFON FORTE
DSC (Chlorzoxazone) Tablets, 500
Milligrams, Was Not Withdrawn From
Sale for Reasons of Safety or
Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) has
determined that PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 milligrams
(mg), were not withdrawn from sale for
reasons of safety or effectiveness. This
determination means that FDA will not
begin procedures to withdraw approval
of abbreviated new drug applications
(ANDAs) that refer to this drug product,
and this determination will allow FDA
to continue to approve ANDAs for
chlorzoxane tablets, 500 mg, if all other
legal and regulatory requirements are
met.
FOR FURTHER INFORMATION CONTACT:
David Faranda, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6213,
Silver Spring, MD 20993–0002, 301–
796–8767.
asabaliauskas on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:33 Jul 13, 2016
Jkt 238001
In 1984,
Congress enacted the Drug Price
Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
(the 1984 amendments), which
authorized the approval of duplicate
versions of drug products under an
ANDA procedure. ANDA applicants
must, with certain exceptions, show that
the drug for which they are seeking
approval contains the same active
ingredient in the same strength and
dosage form as the ‘‘listed drug,’’ which
is a version of the drug that was
previously approved. ANDA applicants
do not have to repeat the extensive
clinical testing otherwise necessary to
gain approval of a new drug application
(NDA).
The 1984 amendments include what
is now section 505(j)(7) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)(7)), which requires FDA to
publish a list of all approved drugs.
FDA publishes this list as part of the
‘‘Approved Drug Products With
Therapeutic Equivalence Evaluations,’’
which is known generally as the
‘‘Orange Book.’’ Under FDA regulations,
drugs are removed from the list if the
Agency withdraws or suspends
approval of the drug’s NDA or ANDA
for reasons of safety or effectiveness or
if FDA determines that the listed drug
was withdrawn from sale for reasons of
safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to
determine, or the Agency may
determine on its own initiative, whether
a listed drug was withdrawn from sale
for reasons of safety or effectiveness.
This determination may be made at any
time after the drug has been withdrawn
from sale, but must be made prior to
approving an ANDA that refers to the
listed drug (§ 314.161 (21 CFR 314.161)).
FDA may not approve an ANDA that
does not refer to a listed drug.
PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, is the
subject of NDA 011529, held by Janssen
Research & Development, LLC, and
initially approved on August 15, 1958.
PARAFON FORTE DSC is indicated as
an adjunct to rest, physical therapy, and
other measures for the relief of
discomfort associated with acute,
painful musculoskeletal conditions.
PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, is listed
in the ‘‘Discontinued Drug Product List’’
section of the Orange Book.
Flamingo Pharmaceuticals Ltd.
submitted a citizen petition dated
November 7, 2015 (Docket No. FDA–
2015–P–4224), under 21 CFR 10.30,
requesting that the Agency determine
whether PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, were
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
45507
withdrawn from sale for reasons of
safety or effectiveness.
After considering the citizen petition
and reviewing Agency records and
based on the information we have at this
time, FDA has determined under
§ 314.161 that PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, were
not withdrawn for reasons of safety or
effectiveness. The petitioner has
identified no data or other information
suggesting that PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, were
withdrawn for reasons of safety or
effectiveness. We have carefully
reviewed our files for records
concerning the withdrawal of
PARAFON FORTE DSC (chlorzoxazone)
tablets, 500 mg, from sale. We have also
independently evaluated relevant
literature and data for possible
postmarketing adverse events. We have
reviewed the available evidence and
determined that this drug product was
not withdrawn from sale for reasons of
safety or effectiveness.
Accordingly, the Agency will
continue to list PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, in the
‘‘Discontinued Drug Product List’’
section of the Orange Book. The
‘‘Discontinued Drug Product List’’
delineates, among other items, drug
products that have been discontinued
from marketing for reasons other than
safety or effectiveness. ANDAs that refer
to PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, may be
approved by the Agency as long as they
meet all other legal and regulatory
requirements for the approval of
ANDAs. If FDA determines that labeling
for this drug product should be revised
to meet current standards, the Agency
will advise ANDA applicants to submit
such labeling.
Dated: July 8, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–16635 Filed 7–13–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2016–N–1678]
The Food and Drug Administration
Foods and Veterinary Medicine
Program’s Strategic Plan for Fiscal
Years 2016–2025
AGENCY:
Food and Drug Administration,
HHS.
Notice and request for
comments.
ACTION:
E:\FR\FM\14JYN1.SGM
14JYN1
]]>Agencies
[Federal Register Volume 81, Number 135 (Thursday, July 14, 2016)]
[Notices]
[Page 45507]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-16635]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-P-4224]
Determination That PARAFON FORTE DSC (Chlorzoxazone) Tablets, 500
Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or
Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) has
determined that PARAFON FORTE DSC (chlorzoxazone) tablets, 500
milligrams (mg), were not withdrawn from sale for reasons of safety or
effectiveness. This determination means that FDA will not begin
procedures to withdraw approval of abbreviated new drug applications
(ANDAs) that refer to this drug product, and this determination will
allow FDA to continue to approve ANDAs for chlorzoxane tablets, 500 mg,
if all other legal and regulatory requirements are met.
FOR FURTHER INFORMATION CONTACT: David Faranda, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6213, Silver Spring, MD 20993-0002, 301-
796-8767.
SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)
(the 1984 amendments), which authorized the approval of duplicate
versions of drug products under an ANDA procedure. ANDA applicants
must, with certain exceptions, show that the drug for which they are
seeking approval contains the same active ingredient in the same
strength and dosage form as the ``listed drug,'' which is a version of
the drug that was previously approved. ANDA applicants do not have to
repeat the extensive clinical testing otherwise necessary to gain
approval of a new drug application (NDA).
The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products With Therapeutic
Equivalence Evaluations,'' which is known generally as the ``Orange
Book.'' Under FDA regulations, drugs are removed from the list if the
Agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness or if FDA determines that the listed
drug was withdrawn from sale for reasons of safety or effectiveness (21
CFR 314.162).
A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale,
but must be made prior to approving an ANDA that refers to the listed
drug (Sec. 314.161 (21 CFR 314.161)). FDA may not approve an ANDA that
does not refer to a listed drug.
PARAFON FORTE DSC (chlorzoxazone) tablets, 500 mg, is the subject
of NDA 011529, held by Janssen Research & Development, LLC, and
initially approved on August 15, 1958. PARAFON FORTE DSC is indicated
as an adjunct to rest, physical therapy, and other measures for the
relief of discomfort associated with acute, painful musculoskeletal
conditions.
PARAFON FORTE DSC (chlorzoxazone) tablets, 500 mg, is listed in the
``Discontinued Drug Product List'' section of the Orange Book.
Flamingo Pharmaceuticals Ltd. submitted a citizen petition dated
November 7, 2015 (Docket No. FDA-2015-P-4224), under 21 CFR 10.30,
requesting that the Agency determine whether PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, were withdrawn from sale for reasons
of safety or effectiveness.
After considering the citizen petition and reviewing Agency records
and based on the information we have at this time, FDA has determined
under Sec. 314.161 that PARAFON FORTE DSC (chlorzoxazone) tablets, 500
mg, were not withdrawn for reasons of safety or effectiveness. The
petitioner has identified no data or other information suggesting that
PARAFON FORTE DSC (chlorzoxazone) tablets, 500 mg, were withdrawn for
reasons of safety or effectiveness. We have carefully reviewed our
files for records concerning the withdrawal of PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, from sale. We have also independently
evaluated relevant literature and data for possible postmarketing
adverse events. We have reviewed the available evidence and determined
that this drug product was not withdrawn from sale for reasons of
safety or effectiveness.
Accordingly, the Agency will continue to list PARAFON FORTE DSC
(chlorzoxazone) tablets, 500 mg, in the ``Discontinued Drug Product
List'' section of the Orange Book. The ``Discontinued Drug Product
List'' delineates, among other items, drug products that have been
discontinued from marketing for reasons other than safety or
effectiveness. ANDAs that refer to PARAFON FORTE DSC (chlorzoxazone)
tablets, 500 mg, may be approved by the Agency as long as they meet all
other legal and regulatory requirements for the approval of ANDAs. If
FDA determines that labeling for this drug product should be revised to
meet current standards, the Agency will advise ANDA applicants to
submit such labeling.
Dated: July 8, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-16635 Filed 7-13-16; 8:45 am]
BILLING CODE 4164-01-P
